Ming Hsieh
Chief Executive Officer at Fulgent Genetics Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Fortinet Inc., 3 years.
Fortinet Inc.
Director
Fulgent Genetics Inc.
Director · Chief Executive Officer
Chief executive roles
Fulgent Genetics Inc.
· Chief Executive Officer
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 11, 2026 | Fortinet Inc. | Option exercise | +650 | — | — |
| Jun 1, 2026 | Fulgent Genetics Inc. | Shares withheld for tax | −4,392 | $18.09 | $79,451 |
| May 26, 2026 | Fulgent Genetics Inc. | Shares withheld for tax | −2,949 | $17.67 | $52,109 |
| Mar 31, 2026 | Fortinet Inc. | Option exercise | +649 | — | — |
| Mar 1, 2026 | Fulgent Genetics Inc. | Shares withheld for tax | −17,566 | $15.33 | $269,287 |
| Feb 26, 2026 | Fulgent Genetics Inc. | Shares withheld for tax | −2,949 | $24.76 | $73,017 |
| Feb 24, 2026 | Fulgent Genetics Inc. | Grant or award | +19,067 | — | — |
| Feb 24, 2026 | Fulgent Genetics Inc. | Grant or award | +39,802 | — | — |
| Feb 24, 2026 | Fulgent Genetics Inc. | Grant or award | +59,276 | — | — |
| Feb 24, 2026 | Fulgent Genetics Inc. | Shares withheld for tax | −10,230 | $23.09 | $236,211 |
| Feb 24, 2026 | Fulgent Genetics Inc. | Shares withheld for tax | −21,354 | $23.09 | $493,064 |
| Feb 24, 2026 | Fulgent Genetics Inc. | Shares withheld for tax | −31,760 | $23.09 | $733,338 |
| Feb 24, 2026 | Fulgent Genetics Inc. | Grant or award | +69,294 | — | — |
| Feb 23, 2026 | Fulgent Genetics Inc. | Shares withheld for tax | −2,167 | $23.01 | $49,863 |
| Dec 31, 2025 | Fortinet Inc. | Option exercise | +649 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.